Sizzling Stock Picks

[SpeculativeHoldings]

COBI - MASTER DD ON THIS INCREDIBLY HOT BIOTECH PLAY








COBI SECURITY DETAILS

OTC MARKETS.COM http://www.otcmarkets.com/stock/COBI/company-info

OUTSTANDING SHARES: 19,842,621!!!!

FULLY REPORTING! LOW FLOAT!AN OTC QB STOCK!





http://www.barchart.com/quotes/stocks/COBI

COBI NEWS IN 2011

Dr. Joseph Sinkule Named as President and Chief Operating Officer of Compass Biotechnologies, Inc.(COBI:OB)
Date: 05/27/2011 @ 8:15AM
Source: PR Newswire
Stock: Compass Biotech (COBI)
http://ih.advfn.com/p.php?pid=nmona&article=47858068

Compass Biotechnologies, Inc. (Compass) (OTCBB: COBI) is pleased to announce the appointment of Dr. Joseph Sinkule to the position of President and Chief Operating Officer (COO) of the Company. Dr. Sinkule has played a leading role in the recent directing of Compass Bio towards the MULTIBILLION DOLLAR bio betters, generic drug markets and development of biosimiliar blockbuster products. The global market for biosimilar products has the potential to exceed $5 BILLION in sales within the next few years as current blockbuster drugs with global sales of over $20 BILLION, have lost their patent protection. Further Dr. Sinkule will also head up C-Pharma Inc's, (a Compass Bio subsidiary company), hepatitis drug development program, which is worth an additional $2 BILLION plus a year.

COMPASS BIOTECHNOLOGIES (COBI:OB) ANNOUNCES MEMORANDUM OF UNDERSTANDING WITH ARECOR LTD., OF CAMBRIDGE U.K. TO DEVELOP HEAT STAB
Date: 04/26/2011 @ 7:00AM
Source: PR Newswire
Stock: Compass Biotech (COBI)
http://ih.advfn.com/p.php?pid=nmona&article=47415279

In continuation of executing on its business plan, the Company is pleased to announce an agreement to develop a heat stable Hepatitis B vaccine formulation based upon acquiring a worldwide exclusive license from ARECOR Ltd. (Cambridge U.K.), using its proprietary Arestat™ formulation technology.

The market for current prophylactic vaccines against hepatitis B is estimated at $800 MILLION, while the global 2010 travel vaccines market was estimated to be worth $2.7 billion. By 2017, the travel vaccines market is estimated to reach $6.6 BILLION, indicating a CAGR of 13%. None of these vaccines are heat stable and if improperly stored they can lose their effectiveness in a short period of time.

Memorandum of Understanding between ARG Vermögensverwaltung AG ("ARG") and Compass Biotechnologies Inc. (COBI:OB) for up to a US
Date: 04/21/2011 @ 9:15AM
Source: PR Newswire
Stock: Compass Biotech (COBI)
http://ih.advfn.com/p.php?pid=nmona&article=47388498

Compass Biotechnologies (COBI:OB) is a product-oriented, specialty pharmaceutical company focused on developing products for multi-billion dollar markets. The Company is pleased to announce that it has received a Memorandum of Understanding from ARG Vermogensverwaltung AG (ARG) of Munich Germany for a financing of up to US$10,000,000.00

COMPASS BIOTECHNOLOGIES (COBI:OB) ANNOUNCES SUPPLEMENTARY PRESS RELEASE FOR NEW WEBSITE
Date: 04/13/2011 @ 4:11PM
Source: PR Newswire
Stock: Compass Biotech (COBI)
http://ih.advfn.com/p.php?pid=nmona&article=47285319

COMPASS BIOTECHNOLOGIES ANNOUNCES MEMORANDUM OF UNDERSTANDING WITH PANGEN BIOTECH INC.
Date: 04/11/2011 @ 8:15AM
Source: PR Newswire
Stock: Compass Biotech (COBI)
http://ih.advfn.com/p.php?pid=nmona&article=47244419

ABOUT COBI

Compass Biotechnologies Inc is a public bio pharmaceutical company (COBI.OB) focused on the commercialization of life-saving products targeted on the multi-billion dollar generic, biosimiliar and bio-better markets.

Additionally, we have created a wholly owned subsidiary company called C-Pharma Inc., which will focus on development of Hepatitis C therapies. To this effect Compass Biotech Inc., the parent company, holds all rights to the worldwide exclusive Hepatitis product licenses and other rights from the National Institutes of Health (NIH). Therefore Compass will focus on the bio generic/ biosimiliarébiobetter product opportunities while C-Pharma will focus on the hepatitis C therapeutic and vaccine market.
VISIT: http:// www.c-pharma.net



Compass Biotechnologies also has an wholly owned subsidiary company called C-Pharma Inc:
This Company through its parent Compass; is charged with the creation of a Hepatitis product development franchise. C-Pharma has acquired the rights to novel vaccine technology which is currently being developed for Hepatitis C applications. This technology was previously developed at the National Institutes of Health (NIH) and licensed to the Company on a worldwide exclusive basis. In addition C-Pharma is developing its own generics for two drugs known as Ribavirin and pegylated alpha interferon. These two drugs are currently the drugs used for patients who are chronically infected with the Hepatitis C virus and in combination are the current standard of care. These two drugs when used together for Hepatitis C chronic infection create a market of $2 BILLION A YEAR worldwide.

MISSION STATEMENT
Our mission is to bring to market therapeutic drugs which are either at a lower price point (generics) or those which offer superior quality (biosimiliars) or enhanced drug properties (Bio Betters).

MANAGEMENT TEAM
Garth Likes
Chief Executive Officer and Chairman, Garth Likes is the founder and CEO of Compass Biotechnologies and of C-Pharma In, Hehas served as CEO and Board member of several public companies and been with the Comapny since its inception in 2007.
Previously Mr. Likes has held positions in large multinational companies and small start-ups. Garth brings considerable knowledge, expertise and energy to Compass and has the industry experience to successfully navigate the Company through financings, corporate operations, and overall management of this public company entity.

Dr. Joseph Sinkule
Founder / Director Dr. Joseph Sinkule is a serial entrepreneur and a 28-year biotech veteran with extensive biotech start up experience. Joe has taken several drug and recombinant protein products from discovery thru FDA approval and licensure. He was previously Sr. VP of R&D at a NASDAQ-listed biotech company and Director of Clinical Research at Immunex. Joe founded five other biotech companies and two CROs, and currently serves on the Boards of four healthcare companies.

Other staff
The Company has begun recruiting additional staff including project management and administrative accounting positions, and is assembling a first-rate team of experienced biotech personnel that are readied for successful execution of the product development programs.

Scientific Advisory Board
The Scientific Advisory Board of the Company will be assembled by Dr. Liang, one of world’s top experts on HCV infection and head of the Liver Disease Section of the NIH. Dr. Liang is the co-inventor of the Company’s patented HCV VLP vaccine technology. Top-notched scientific expertise recruited to the SAB will help guide our direction by proving valuable technical and clinical input.
Board of Directors
Currently Mr. Likes and Dr. Sinkule serve on the board. An industry-experienced Board of Directors from around the country will be recruited over the next 3–6 months to advise the management team and represent the shareholders of the Company. The Board will be comprised predominantly of independent experts contributing various expertise and insight as to overall management and value creation for the Company.

RECENT SEC FILINGS
- Annual Report (10-K)
Date: 05/18/2011 @ 6:02AM
Source: Edgar (US Regulatory)
Stock: (COBI)
http://ih.advfn.com/p.php?pid=nmona&article=47728940

- Amended Current report filing (8-K/A)
Date: 04/12/2011 @ 5:29PM
Source: Edgar (US Regulatory)
Stock: (COBI)
http://ih.advfn.com/p.php?pid=nmona&article=47269926

- Current report filing (8-K)
Date: 04/04/2011 @ 3:13PM
Source: Edgar (US Regulatory)
Stock: (COBI)
http://ih.advfn.com/p.php?pid=nmona&article=47157482


INVESTOR INFORMATION
Compass Biotechnologies (COBI:OB)
The Company’s near-term plans are to submit market applications in multiple countries for Compass’s generic, biosimiliar and bio better products as well as to complete C-Pharma’s antiviral generic drugs and to complete Phase I safety, immunology & efficacy studies of the HCV vaccine in humans. The two Companies together will create value by achieving major developmental milestones, by generating revenue from the sales of drug products and obtaining proof in humans that VLP vaccine immunization leads to development of neutralizing antibodies that attack the HCV virus and prevent infection.

The Company will continue to advance the development of other anti-viral pipeline products and we plan to begin Phase I safety studies of the VLP vaccine as a potential anti-viral immunotherapy for treating chronic HCV infection. An antibody product derived from healthy volunteers administered VLP vaccine inoculations will be evaluated as a passive immunotherapy product in patients undergoing liver transplantation to prevent or significantly delay the liver graft re-infection by the hepatitis C virus.
Inquiries contact:

Mr. Garth Likes, President/CEO
[e-mail]

Compass Biotechnologies /C-Pharma Inc.
Advanced Technology Center
9650-20th Avenue, Suite 131
Edmonton, Alberta, Canada
Phone [phone]

COBI CHARTS